Last reviewed · How we verify
Captopril and Trandolapril
Both captopril and trandolapril inhibit angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure.
Both captopril and trandolapril inhibit angiotensin-converting enzyme (ACE), reducing the formation of angiotensin II and lowering blood pressure. Used for Hypertension, Heart failure, Post-myocardial infarction.
At a glance
| Generic name | Captopril and Trandolapril |
|---|---|
| Sponsor | Rigshospitalet, Denmark |
| Drug class | ACE inhibitor |
| Target | Angiotensin-converting enzyme (ACE) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
ACE inhibitors block the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, resulting in lower blood pressure and reduced cardiac workload. These agents are commonly used in hypertension and heart failure management.
Approved indications
- Hypertension
- Heart failure
- Post-myocardial infarction
- Diabetic nephropathy
Common side effects
- Dry cough
- Dizziness
- Hyperkalemia
- Angioedema
- Hypotension
- Fatigue
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery (PHASE4)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Captopril and Trandolapril CI brief — competitive landscape report
- Captopril and Trandolapril updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI